RAB31

Across TCGA pan-cancer cohorts, RAB31 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAB31 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RAB31 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB31 expression acts as an unfavorable survival marker.

LIHC, LUAD, and COAD are the cancer types where RAB31 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.037	0.556	<.001	24	view →
LUAD	OS	Median	All	0.281	0.812	.008	9	view →
COAD	DFS	Median	III,IV	0.170	0.697	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RAB31–LIHC (DFS)

Open the LIHC breakdown →